Search details
1.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
PLoS Genet
; 19(1): e1010563, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36595552
2.
Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
Breast Cancer Res Treat
; 205(1): 39-48, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38265569
3.
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anticancer Drugs
; 33(1): e628-e634, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34407044
4.
Ten-year outcome results of cT4 breast cancer after neoadjuvant treatment.
J Surg Oncol
; 124(8): 1242-1250, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34472105
5.
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
Br J Cancer
; 121(4): 325-331, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31303642
6.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
BMC Cancer
; 19(1): 902, 2019 Sep 10.
Article
in English
| MEDLINE | ID: mdl-31500588
7.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Article
in English
| MEDLINE | ID: mdl-29589138
8.
Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
Int J Cancer
; 139(1): 212-9, 2016 Jul 01.
Article
in English
| MEDLINE | ID: mdl-26916107
9.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27372069
10.
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Future Oncol
; 12(3): 373-87, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26584409
11.
Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Future Oncol
; 12(17): 2001-8, 2016 Sep.
Article
in English
| MEDLINE | ID: mdl-27255717
12.
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Lancet Oncol
; 15(4): 406-14, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24636208
13.
Reply to Comments on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines."
Br J Cancer
; 121(9): 806, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31527688
14.
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
Breast Cancer Res Treat
; 146(3): 573-82, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-25007961
15.
Correction: A Machine Learning Model to Predict Patients' Adherence Behavior and a Decision Support System for Patients With Metastatic Breast Cancer: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
; 13: e55928, 2024 Jan 15.
Article
in English
| MEDLINE | ID: mdl-38224582
16.
Support for Chronic Pain Management for Breast Cancer Survivors Through Novel Digital Health Ecosystems: Pilot Usability Study of the PainRELife Mobile App.
JMIR Form Res
; 8: e51021, 2024 Feb 02.
Article
in English
| MEDLINE | ID: mdl-38306176
17.
Therapeutic effect of ß-blockers in triple-negative breast cancer postmenopausal women.
Breast Cancer Res Treat
; 140(3): 567-75, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23912960
18.
Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases.
Breast Cancer Res Treat
; 138(1): 303-10, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-23412771
19.
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
Acta Oncol
; 52(8): 1649-56, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-23327413
20.
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.
Cancers (Basel)
; 15(5)2023 Feb 22.
Article
in English
| MEDLINE | ID: mdl-36900178